4.7 Article

T cell-directed therapies: lessons learned and future prospects

期刊

NATURE IMMUNOLOGY
卷 8, 期 1, 页码 25-30

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ni1429

关键词

-

资金

  1. Intramural NIH HHS Funding Source: Medline
  2. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041174, Z01AR041159, ZIAAR041159, Z01AR041133, Z01AR041106, ZIAAR041106, ZIAAR041133, ZIAAR041174] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055111, ZIADK055112, ZIADK062002, ZIADK055111, Z01DK055112, Z01DK062002] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Agents interfering with T cell function are therapeutic mainstays for various autoimmune diseases and for transplant approaches to organ failure. The understanding of T cell biology has blossomed since the development of most agents now in use. Here we discuss T cell - specific agents now in use, others recently added to the therapeutic armamentarium and promising agents being investigated in clinical and preclinical studies. In addition, we reflect on the risks and benefits involved in the testing of such agents clinically, with examples of agents that have successfully been used in the clinic and agents that failed to reach therapeutic use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据